Global Artificial Intelligence Drug Development Market Research Report 2023

Publication ID:

PB502235926

Publication Date:

February 2, 2023

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Highlights
The global Artificial Intelligence Drug Development market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Artificial Intelligence Drug Development is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Artificial Intelligence Drug Development is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Artificial Intelligence Drug Development in Tumor is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Artificial Intelligence Drug Development include Insilico Medicine, Cyclica, XtalPi Inc., Exscientia Limited, AiCure, LLC, Atomwise, Biovista Inc., 叠谤别驳锛孖苍肠. and Numerate, etc. In 2022, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Artificial Intelligence Drug Development, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Artificial Intelligence Drug Development.
The Artificial Intelligence Drug Development market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Artificial Intelligence Drug Development market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Artificial Intelligence Drug Development companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Insilico Medicine
Cyclica
XtalPi Inc.
Exscientia Limited
AiCure, LLC
Atomwise
Biovista Inc.
叠谤别驳锛孖苍肠.
Numerate
Cloud Pharmaceuticals
IBM
NuMedii
BenevolentAI
Lam Therapeutics
Segment by Type
Drug Design
Drug Synthesis
Other
Segment by Application
Tumor
Nervous System
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Artificial Intelligence Drug Development companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Artificial Intelligence Drug Development Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Drug Design
1.2.3 Drug Synthesis
1.2.4 Other
1.3 Market by Application
1.3.1 Global Artificial Intelligence Drug Development Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Tumor
1.3.3 Nervous System
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Artificial Intelligence Drug Development Market Perspective (2018-2029)
2.2 Artificial Intelligence Drug Development Growth Trends by Region
2.2.1 Global Artificial Intelligence Drug Development Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Artificial Intelligence Drug Development Historic Market Size by Region (2018-2023)
2.2.3 Artificial Intelligence Drug Development Forecasted Market Size by Region (2024-2029)
2.3 Artificial Intelligence Drug Development Market Dynamics
2.3.1 Artificial Intelligence Drug Development Industry Trends
2.3.2 Artificial Intelligence Drug Development Market Drivers
2.3.3 Artificial Intelligence Drug Development Market Challenges
2.3.4 Artificial Intelligence Drug Development Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Artificial Intelligence Drug Development Players by Revenue
3.1.1 Global Top Artificial Intelligence Drug Development Players by Revenue (2018-2023)
3.1.2 Global Artificial Intelligence Drug Development Revenue Market Share by Players (2018-2023)
3.2 Global Artificial Intelligence Drug Development Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Artificial Intelligence Drug Development Revenue
3.4 Global Artificial Intelligence Drug Development Market Concentration Ratio
3.4.1 Global Artificial Intelligence Drug Development Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Artificial Intelligence Drug Development Revenue in 2022
3.5 Artificial Intelligence Drug Development Key Players Head office and Area Served
3.6 Key Players Artificial Intelligence Drug Development Product Solution and Service
3.7 Date of Enter into Artificial Intelligence Drug Development Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Artificial Intelligence Drug Development Breakdown Data by Type
4.1 Global Artificial Intelligence Drug Development Historic Market Size by Type (2018-2023)
4.2 Global Artificial Intelligence Drug Development Forecasted Market Size by Type (2024-2029)
5 Artificial Intelligence Drug Development Breakdown Data by Application
5.1 Global Artificial Intelligence Drug Development Historic Market Size by Application (2018-2023)
5.2 Global Artificial Intelligence Drug Development Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Artificial Intelligence Drug Development Market Size (2018-2029)
6.2 North America Artificial Intelligence Drug Development Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Artificial Intelligence Drug Development Market Size by Country (2018-2023)
6.4 North America Artificial Intelligence Drug Development Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Artificial Intelligence Drug Development Market Size (2018-2029)
7.2 Europe Artificial Intelligence Drug Development Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Artificial Intelligence Drug Development Market Size by Country (2018-2023)
7.4 Europe Artificial Intelligence Drug Development Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Artificial Intelligence Drug Development Market Size (2018-2029)
8.2 Asia-Pacific Artificial Intelligence Drug Development Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Artificial Intelligence Drug Development Market Size by Region (2018-2023)
8.4 Asia-Pacific Artificial Intelligence Drug Development Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Artificial Intelligence Drug Development Market Size (2018-2029)
9.2 Latin America Artificial Intelligence Drug Development Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Artificial Intelligence Drug Development Market Size by Country (2018-2023)
9.4 Latin America Artificial Intelligence Drug Development Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Artificial Intelligence Drug Development Market Size (2018-2029)
10.2 Middle East & Africa Artificial Intelligence Drug Development Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Artificial Intelligence Drug Development Market Size by Country (2018-2023)
10.4 Middle East & Africa Artificial Intelligence Drug Development Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Insilico Medicine
11.1.1 Insilico Medicine Company Detail
11.1.2 Insilico Medicine Business Overview
11.1.3 Insilico Medicine Artificial Intelligence Drug Development Introduction
11.1.4 Insilico Medicine Revenue in Artificial Intelligence Drug Development Business (2018-2023)
11.1.5 Insilico Medicine Recent Development
11.2 Cyclica
11.2.1 Cyclica Company Detail
11.2.2 Cyclica Business Overview
11.2.3 Cyclica Artificial Intelligence Drug Development Introduction
11.2.4 Cyclica Revenue in Artificial Intelligence Drug Development Business (2018-2023)
11.2.5 Cyclica Recent Development
11.3 XtalPi Inc.
11.3.1 XtalPi Inc. Company Detail
11.3.2 XtalPi Inc. Business Overview
11.3.3 XtalPi Inc. Artificial Intelligence Drug Development Introduction
11.3.4 XtalPi Inc. Revenue in Artificial Intelligence Drug Development Business (2018-2023)
11.3.5 XtalPi Inc. Recent Development
11.4 Exscientia Limited
11.4.1 Exscientia Limited Company Detail
11.4.2 Exscientia Limited Business Overview
11.4.3 Exscientia Limited Artificial Intelligence Drug Development Introduction
11.4.4 Exscientia Limited Revenue in Artificial Intelligence Drug Development Business (2018-2023)
11.4.5 Exscientia Limited Recent Development
11.5 AiCure, LLC
11.5.1 AiCure, LLC Company Detail
11.5.2 AiCure, LLC Business Overview
11.5.3 AiCure, LLC Artificial Intelligence Drug Development Introduction
11.5.4 AiCure, LLC Revenue in Artificial Intelligence Drug Development Business (2018-2023)
11.5.5 AiCure, LLC Recent Development
11.6 Atomwise
11.6.1 Atomwise Company Detail
11.6.2 Atomwise Business Overview
11.6.3 Atomwise Artificial Intelligence Drug Development Introduction
11.6.4 Atomwise Revenue in Artificial Intelligence Drug Development Business (2018-2023)
11.6.5 Atomwise Recent Development
11.7 Biovista Inc.
11.7.1 Biovista Inc. Company Detail
11.7.2 Biovista Inc. Business Overview
11.7.3 Biovista Inc. Artificial Intelligence Drug Development Introduction
11.7.4 Biovista Inc. Revenue in Artificial Intelligence Drug Development Business (2018-2023)
11.7.5 Biovista Inc. Recent Development
11.8 叠谤别驳锛孖苍肠.
11.8.1 叠谤别驳锛孖苍肠. Company Detail
11.8.2 叠谤别驳锛孖苍肠. Business Overview
11.8.3 叠谤别驳锛孖苍肠. Artificial Intelligence Drug Development Introduction
11.8.4 叠谤别驳锛孖苍肠. Revenue in Artificial Intelligence Drug Development Business (2018-2023)
11.8.5 叠谤别驳锛孖苍肠. Recent Development
11.9 Numerate
11.9.1 Numerate Company Detail
11.9.2 Numerate Business Overview
11.9.3 Numerate Artificial Intelligence Drug Development Introduction
11.9.4 Numerate Revenue in Artificial Intelligence Drug Development Business (2018-2023)
11.9.5 Numerate Recent Development
11.10 Cloud Pharmaceuticals
11.10.1 Cloud Pharmaceuticals Company Detail
11.10.2 Cloud Pharmaceuticals Business Overview
11.10.3 Cloud Pharmaceuticals Artificial Intelligence Drug Development Introduction
11.10.4 Cloud Pharmaceuticals Revenue in Artificial Intelligence Drug Development Business (2018-2023)
11.10.5 Cloud Pharmaceuticals Recent Development
11.11 IBM
11.11.1 IBM Company Detail
11.11.2 IBM Business Overview
11.11.3 IBM Artificial Intelligence Drug Development Introduction
11.11.4 IBM Revenue in Artificial Intelligence Drug Development Business (2018-2023)
11.11.5 IBM Recent Development
11.12 NuMedii
11.12.1 NuMedii Company Detail
11.12.2 NuMedii Business Overview
11.12.3 NuMedii Artificial Intelligence Drug Development Introduction
11.12.4 NuMedii Revenue in Artificial Intelligence Drug Development Business (2018-2023)
11.12.5 NuMedii Recent Development
11.13 BenevolentAI
11.13.1 BenevolentAI Company Detail
11.13.2 BenevolentAI Business Overview
11.13.3 BenevolentAI Artificial Intelligence Drug Development Introduction
11.13.4 BenevolentAI Revenue in Artificial Intelligence Drug Development Business (2018-2023)
11.13.5 BenevolentAI Recent Development
11.14 Lam Therapeutics
11.14.1 Lam Therapeutics Company Detail
11.14.2 Lam Therapeutics Business Overview
11.14.3 Lam Therapeutics Artificial Intelligence Drug Development Introduction
11.14.4 Lam Therapeutics Revenue in Artificial Intelligence Drug Development Business (2018-2023)
11.14.5 Lam Therapeutics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Insilico Medicine
Cyclica
XtalPi Inc.
Exscientia Limited
AiCure, LLC
Atomwise
Biovista Inc.
叠谤别驳锛孖苍肠.
Numerate
Cloud Pharmaceuticals
IBM
NuMedii
BenevolentAI
Lam Therapeutics

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂